Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT02283775 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02283775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
May 15, 2015
Completion date
May 26, 2021
Enrollment
54 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma